563 related articles for article (PubMed ID: 3071336)
1. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
2. Chronic occult intra-alveolar hemorrhage: a rare cause of failure to respond to erythropoietin.
Conlon PJ; O'Neill S; O'Neill G; Kelly F; Donohoe J
Clin Nephrol; 1994 Feb; 41(2):83-5. PubMed ID: 8004833
[TBL] [Abstract][Full Text] [Related]
3. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
Sobota JT
Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
[No Abstract] [Full Text] [Related]
7. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
8. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
9. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.
Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P
Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151
[No Abstract] [Full Text] [Related]
10. Biological characterization of recombinant human erythropoietin.
Krumwieh D; Arnold I; Seiler FR
Behring Inst Mitt; 1988 Aug; (83):193-201. PubMed ID: 3240225
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
[TBL] [Abstract][Full Text] [Related]
12. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
13. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease.
Kühn K; Nonnast-Daniel B; Grützmacher P; Grüner J; Pfåffl W; Baldamus CA; Scigalla P
Contrib Nephrol; 1988; 66():94-103. PubMed ID: 3292152
[No Abstract] [Full Text] [Related]
14. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
Alexander SR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin use in pregnancy: two cases and a review of the literature.
Scott LL; Ramin SM; Richey M; Hanson J; Gilstrap LC
Am J Perinatol; 1995 Jan; 12(1):22-4. PubMed ID: 7710570
[TBL] [Abstract][Full Text] [Related]
16. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
17. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA
Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909
[TBL] [Abstract][Full Text] [Related]
18. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin therapy in patients with chronic renal failure.
Pinevich AJ; Petersen J
West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
[TBL] [Abstract][Full Text] [Related]
20. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
